1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Samsung Bioepis Outlines European Eculizumab Roll-Out

Epysqli Rival To Soliris Is First Biosimilar Solely Commercialized By Firm In Europe

 
• By Dave Wallace

Samsung Bioepis has offered details on the launch of its Epysqli eculizumab biosimilar rival to Soliris in European markets.

Europe at night seen from space
Samsung Bioepis has started selling Epysqli in European markets • Source: Shutterstock

Germany, Spain and Italy are the initial launch markets for Samsung Bioepis’s Epysqli (eculizumab) biosimilar rival to Soliris in Europe, the company has revealed, detailing the initial steps of its roll-out in response to enquiries from Generics Bulletin.

Key Takeaways:

  • Samsung Bioepis’s Epysqli (eculizumab) biosimilar rival to Soliris, approved in Europe in May, has been launched in Germany in July and Spain and Italy in September.

  • This will be the first biosimilar solely commercialized by Samsung Bioepis in Europe, following previous launches through its partnership with Biogen.

  • Other European launches are in the works but Samsung Bioepis is “not in a position to specify the timeline at this time

Epysqli was approved in May this year, following an endorsement from the from the Committee for Medicinal Products for Human Use within the European Medicines Agency in March

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”